Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Cancer Med ; 11(13): 2662-2678, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35621231

RESUMO

BACKGROUND: Cancers are leading causes of mortality and morbidity, with smoking being recognized as a significant risk factor for many types of cancer. We aimed to report the cancer burden attributable to tobacco smoking by sex, age, socio-demographic index (SDI), and cancer type in 204 countries and territories from 1990 to 2019. METHODS: The burden of cancers attributable to smoking was reported between 1990 and 2019, based upon the Comparative Risk Assessment approach used in the Global Burden of Disease (GBD) study 2019. RESULTS: Globally, in 2019 there were an estimated 2.5 million cancer-related deaths (95% UI: 2.3 to 2.7) and 56.4 million DALYs (51.3 to 61.7) attributable to smoking. The global age-standardized death and DALY rates of cancers attributable to smoking per 100,000 decreased by 23.0% (-29.5 to -15.8) and 28.6% (-35.1 to -21.5), respectively, over the period 1990-2019. Central Europe (50.4 [44.4 to 57.6]) and Western Sub-Saharan Africa (6.7 [5.7 to 8.0]) had the highest and lowest age-standardized death rates, respectively, for cancers attributable to smoking. In 2019, the age-standardized DALY rate of cancers attributable to smoking was highest in Greenland (2224.0 [1804.5 to 2678.8]) and lowest in Ethiopia (72.2 [51.2 to 98.0]). Also in 2019, the global number of DALYs was highest in the 65-69 age group and there was a positive association between SDI and the age-standardized DALY rate. CONCLUSIONS: The results of this study clearly illustrate that renewed efforts are required to increase utilization of evidence-based smoking cessation support in order to reduce the burden of smoking-related diseases.


Assuntos
Carga Global da Doença , Neoplasias , Etiópia , Saúde Global , Humanos , Neoplasias/epidemiologia , Neoplasias/etiologia , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Risco , Fumar Tabaco/efeitos adversos , Fumar Tabaco/epidemiologia
2.
Artigo em Inglês | MEDLINE | ID: mdl-35249462

RESUMO

Exhaled breath condensate (EBC) is used to investigate the efficacy of EBC to detect the genetic mutations in patients with lung cancer. Samples of 5 patients and 5 healthy volunteers were collected. DNA was extracted and used for amplification of hotspot regions of TP53 and KRAS genes by using PCR. We performed the mutation analysis by direct sequencing in all subjects. Detected mutations in EBC samples were compared with those of corresponding tumor tissues and there was complete agreement within the detected mutations in EBC and tumorous tissue. EBC can be used as an efficient and noninvasive source for the assessment of gene mutations in patients with lung cancer.


Assuntos
Testes Respiratórios , Neoplasias Pulmonares , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Mutação , Projetos Piloto , Reação em Cadeia da Polimerase
3.
Chest ; 161(2): 318-329, 2022 02.
Artigo em Inglês | MEDLINE | ID: mdl-34699773

RESUMO

BACKGROUND: Understanding global trends in the point prevalence, deaths, and disability-adjusted life-years (DALYs) for asthma will facilitate evidence-based decision-making. RESEARCH QUESTION: What are the global, regional, and national burdens of asthma in 204 countries and territories between 1990 and 2019 by age, sex, and sociodemographic index (SDI)? STUDY DESIGN AND METHODS: Publicly available data from the Global Burden of Disease study from 1990 through 2019 were used. All estimates were presented as counts and age-standardized rates per 100,000, along with their associated uncertainty intervals. RESULTS: In 2019, the global age-standardized point prevalence and death rates for asthma were 3,415.5 and 5.8 per 100,000, which represent a 24% and 51.3% decrease since 1990, respectively. Moreover, in 2019, the global age-standardized DALY rate was 273.6 and the global point prevalence of asthma was highest in the group 5 to 9 years of age. Also in 2019, the United States (10,399.3) showed the highest age-standardized point prevalence rate of asthma. Generally, the burden of asthma decreased with increasing SDI. Globally, high BMI (16.9%), smoking (9.9%), and occupational asthmagens (8.8%) contributed to the 2019 asthma DALYs. INTERPRETATION: Asthma remains an important public health issue, particularly in regions with low socioeconomic development. Future research is needed to examine thoroughly the associations asthma has with its risk factors and the factors impeding optimal self-management. Further research also is needed to understand and implement better the interventions that have reduced the burden of asthma.


Assuntos
Asma/epidemiologia , Asma/mortalidade , Asma/fisiopatologia , Anos de Vida Ajustados por Deficiência , Saúde Global , Feminino , Humanos , Masculino , Prevalência , Fatores de Risco
4.
J Thorac Oncol ; 16(6): 945-959, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-33866016

RESUMO

INTRODUCTION: Understanding trends in the annual incidence, mortality, and disability-adjusted life-years (DALYs) for tracheal, bronchus, and lung (TBL) cancer globally is important to enable appropriate targeting of resources for prevention, clinical practice improvement, and research. The aim of this study was to determine the global, regional, and national burdens of TBL cancer in 204 countries and territories from 1990 to 2019 by age, sex, and sociodemographic index. METHODS: Estimates were produced through various data inputs including the following: cancer registries (nsite-years = 5318), vital registration (nsite-years = 22,553), vital registration-sample (nsite-years = 825), and verbal autopsies (nsite-years = 516). Annual incidence, mortality, and DALYs were estimated and presented as counts and age-standardized rates per 100,000 population. RESULTS: There were 2.3 million (95% uncertainty interval [UI]: 2.1-2.5) incident cases of TBL cancer, with an age-standardized annual incidence rate of 27.7 (95% UI: 25.3-30), which decreased by 2.6% (95% UI: -12.4 to 6.5) between 1990 and 2019. TBL cancer was responsible for 2 million (95% UI: 1.9-2.2) deaths globally with an age-standardized death rate of 25.2 (95% UI: 23.2-27), a decrease of 7.8% (95% UI: -15.9 to 0.2) between 1990 and 2019. Moreover, TBL accounted for 45.9 million (95% UI: 42.3-49.3) DALYs at the global level, with an age-standardized rate of 551.6 (95% UI: 509-593.1) DALYs per 100,000 population. The standardized DALY rate declined by 16.2% (95% UI: -24 to -8.2) from 1990 to 2019. Greenland (77.7 [95% UI: 64.4-90.6]), Monaco (75.6 [95% UI: 61.4-90.8]), and Montenegro (56.7 [95% UI: 46.5-68.9]) had the three highest age-standardized annual incidence rates. The aforementioned three countries also had the three highest age-standardized death and DALY rates of TBL cancer. Honduras (68% [95% UI: 14.5-137.7]), Cabo Verde (62.2% [95% UI: 24.1-101.3]), and Monaco (58.2% [95% UI: 19.2-109.7]) had the largest increase in age-standardized annual incidence rates for TBL cancer during 1990 to 2019. The largest increases were found in age-standardized death rates of TBL cancer in Honduras (67.1% [95% UI: 14.7-133.1]), Cabo Verde (64.4% [95% UI: 25-103.4]), and Mozambique (49.9% [95% UI: 7.9 -101.3]). Age-standardized annual incidence and death rates were higher in male than female individuals and increased with population aging. There were nonlinear but generally positive associations between age-standardized DALY rates with corresponding sociodemographic index of countries. Globally, smoking (62.4%), ambient particulate matter (15.3%), and high fasting plasma glucose (9.9%) had the top three highest percent of attributable DALYs owing to TBL cancer in 2019 for both sexes. CONCLUSIONS: This study found a decline in burden globally but with some countries having an increase. These results are crucial to set priorities for prevention and treatment of TBL cancer and would be beneficial for policymakers, government officials, clinicians, and researchers.


Assuntos
Carga Global da Doença , Neoplasias Pulmonares , Brônquios , Feminino , Humanos , Incidência , Neoplasias Pulmonares/epidemiologia , Masculino , Prevalência , Anos de Vida Ajustados por Qualidade de Vida , Fatores de Risco
6.
J Cardiovasc Thorac Res ; 7(1): 13-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25859310

RESUMO

INTRODUCTION: Prevention of pulmonary complications after coronary artery bypass graft is attended as a very important issue. The aim of this study was to evaluate the role of pulmonary rehabilitation before surgery for reducing the risk of pulmonary complications after surgery. METHODS: In a randomized clinical trial, 60 patients undergoing heart surgery were randomly divided into two groups A and B. Chest physiotherapy was performed before and after surgery on group A patients however it was done on group B's, only after surgery. Effects of preoperative pulmonary rehabilitation were compared between two groups, using spirometry and arterial blood gas (ABG). RESULTS: Thirty nine males (65%) and 21 females (35%) with mean age of 8.10 ± 9.56 were analyzed. The mean differences were statistically significant for predicted forced vital capacity (FVC) (CI 95%:1.3 to 8.7) and Predicted Peak Flow indices (PEF) (CI 95%: 1.9 to 9.4) of spirometry indicator, PCO2 index (of ABG parameter) (CI 95%: 1.4 to 8.9) and mean oxygen saturation (mean Spo2) (CI 95%: 0.6 to 1.7) of ABG index in two groups. CONCLUSION: The performance of pulmonary rehabilitation program before surgery is recommended, as it may result in the reduction of complications of heart surgery.

7.
Pneumologia ; 60(3): 164-5, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22097441

RESUMO

Mucoepidermoid carcinoma is a relatively common salivary glands tumor. This tumor is characterized by mucus secretion, cell type can be intermediate or squamous. Mucoepidermoid carcinoma of the bronchi and especially trachea is very unusual. We are reporting the case of a 22 years old female who presented with main complaint of exertional dyspnea and stridor for about 2 month. Bronchoscopy examination showed a mass with smooth surface in trachea. After surgery a low grade mucoepidermoid carcinoma was confirmed by pathological examination.


Assuntos
Broncoscopia , Carcinoma Mucoepidermoide/patologia , Carcinoma Mucoepidermoide/cirurgia , Neoplasias da Traqueia/patologia , Neoplasias da Traqueia/cirurgia , Carcinoma Mucoepidermoide/complicações , Carcinoma Mucoepidermoide/diagnóstico , Diagnóstico Diferencial , Dispneia/etiologia , Feminino , Humanos , Sons Respiratórios/etiologia , Toracotomia/métodos , Neoplasias da Traqueia/complicações , Neoplasias da Traqueia/diagnóstico , Resultado do Tratamento , Adulto Jovem
8.
J Bronchology Interv Pulmonol ; 18(4): 362-4, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23208635

RESUMO

Hydatid cyst is a common clinical challenge in endemic areas. Atypical clinical presentation and radiologic findings may occasionally lead to misdiagnosis. We report the case of a 22-year-old woman who presented with chief complaints of cough and hemoptysis of 2 months' duration. Bronchoscopic examination revealed a smooth, necrotic-looking endobronchial lesion, producing total occlusion of the superior segment of the left lower lobe. This lesion was completely removed using a flexible bronchoscope. Diagnosis of hydatid cyst was confirmed by pathologic examination.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA